Verizon to cut 15,000 jobs amid growing competition pressures - WSJ
Investing.com -- Protagenic Therapeutics Inc. (NASDAQ:PTIX) stock climbed 6.8% Thursday after the biopharmaceutical company announced it had completed enrollment and dosing in its Multiple Ascending Dose (MAD) Phase 1 study for its lead compound PT00114.
The clinical milestone represents progress in the development of the company’s peptide-based therapeutic designed to treat stress-related neuropsychiatric and neurodegenerative disorders. The study evaluated the safety and tolerability of PT00114 in healthy volunteers receiving multiple doses over time.
"We’ve completed all dosing for all healthy volunteers in the Phase 1 Study," said Dr. Garo Armen, Executive Chairman of Protagenic Therapeutics. "We plan to deliver a full summation of our analysis of the safety results within by the end of the month."
According to the company, top-line results from the MAD study are expected to be released by November 30th. This follows Protagenic’s earlier completion of a single ascending dose study in early 2025.
PT00114 is being developed as a potential first-in-class therapeutic aimed at restoring resilience and balance in individuals suffering from chronic stress and its neurological consequences. The positive market reaction reflects investor interest in the company’s progress through clinical development stages.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.